GLIPR1L2
GLIPR1-like protein 2
Also known as: GRPL2_HUMAN, MGC39497
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q4G1C9
- Gene
- GLIPR1L2
- Ensembl
- ENSG00000180481
- Chromosome
- 12
- Canonical length
- 344 aa
- Protein class
- Predicted intracellular proteins, Predicted membrane proteins
- Subcellular location
- Golgi apparatus,Vesicles
OverviewNCBI Gene
This gene encodes a member of the cysteine-rich secretory protein, antigen 5, and pathogenesis-related 1 superfamily. Members of this family have roles in a variety of processes, including cancer and immune defense. This gene is located in a cluster with two related genes on chromosome 12. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2012]
Canonical amino-acid sequenceUniProt
344 residues, UniProt reviewed canonical sequence.
>Q4G1C9|GLIPR1L2
1 MEAARPFARE WRAQSLPLAV GGVLKLRLCE LWLLLLGSSL NARFLPDEED VDFINEYVNL
61 HNELRGDVIP RGSNLRFMTW DVALSRTARA WGKKCLFTHN IYLQDVQMVH PKFYGIGENM
121 WVGPENEFTA SIAIRSWHAE KKMYNFENGS CSGDCSNYIQ LVWDHSYKVG CAVTPCSKIG
181 HIIHAAIFIC NYAPGGTLTR RPYEPGIFCT RCGRRDKCTD FLCSNADRDQ ATYYRFWYPK
241 WEMPRPVVCD PLCTFILLLR ILCFILCVIT VLIVQSQFPN ILLEQQMIFT PEESEAGNEE
301 EEKEEEKKEK EEMEMEIMEM EEEKEEREEE EEETQKEKME EEEKLocalizationUniProt · AlphaFold · HPA
Whether an antibody against GLIPR1L2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.38
- Highest tissue expression
- 44 nTPM
Expression across tissuesHPA
Tissue
- testis: 44 nTPM
- spinal cord: 6.1 nTPM
- midbrain: 5.2 nTPM
- ovary: 5.2 nTPM
- amygdala: 3.8 nTPM
- basal ganglia: 3.8 nTPM
Single-cell type
- late primary spermatocytes: 613 nCPM
- early spermatids: 196 nCPM
- early primary spermatocytes: 153 nCPM
- ependymal cells: 33 nCPM
- pituitary stem cells: 32 nCPM
- oligodendrocyte progenitor cells: 27 nCPM
Immune cell
- T-reg: 1 nTPM
- naive CD8 T-cell: 0.9 nTPM
- plasmacytoid DC: 0.7 nTPM
- basophil: 0.6 nTPM
- memory CD8 T-cell: 0.6 nTPM
- naive CD4 T-cell: 0.6 nTPM
Brain region
- white matter: 16 nTPM
- cerebellum: 15 nTPM
- cerebral cortex: 15 nTPM
- basal ganglia: 14 nTPM
- amygdala: 14 nTPM
- hypothalamus: 14 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.45
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.08
- DepMap mean gene effect
- -0.03
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads GLIPR1L2 as an antibody target. Whether an autoantibody or antibody against GLIPR1L2 could matter depends on whether native GLIPR1L2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
GLIPR1L2 is annotated as secreted, so native GLIPR1L2 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label GLIPR1L2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...